Rocket Pharmaceuticals (RCKT) Preferred Stock Liabilities (2014 - 2015)

Rocket Pharmaceuticals has disclosed Preferred Stock Liabilities across 2 years of filings, most recently posting $46.4 million for Q3 2015.

• Preferred Stock Liabilities for Q3 2015 came in at $46.4 million, changed N/A year-over-year; the trailing twelve-month figure through Sep 2015 was $46.4 million (changed N/A YoY), and the FY2014 annual result was $46.8 million, changed N/A from the prior year.
• Preferred Stock Liabilities came in at $46.4 million for Q3 2015 at Rocket Pharmaceuticals, roughly flat from $46.4 million in the prior quarter.
• In the past five years, Preferred Stock Liabilities ranged from a high of $46.8 million in Q4 2014 to a low of $46.4 million in Q1 2015.